Carmustine-impregnated wafers and their impact in the management of high-grade glioma

Bibliography

• Jemal A, Siegal R, Xu J, Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
   PubMed Web of Science ®Google Scholar
• CBTRUS Statistical Report. Primary brain and central nervous system tumors diagnosed in the United States in 2004 – 2007, February 2011
   Google Scholar
• Walker MD, Green SB, Byar DP, Radomized comparisons of radiotherapy and nitrosureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303:1323-9
   PubMed Web of Science ®Google Scholar
• Kristiansen K, Hagen S, Kollevoid T, Combined modality therapy of operated astrocytomas gadre III and IV. Confirmation of the value of postoperative radiation and lack of potentiation of bleomycin on survival time: a propective multicenter trial of the scandinavian glioblastoma study group. Cancer 1981;47:649-52
   PubMed Web of Science ®Google Scholar
• Stewart LA. On behalf of the glioma meta-analysis trialist group. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011-18
   PubMed Web of Science ®Google Scholar
• Medical Research Council Brain Tumour Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: A Medical Research Council Trial. J Clin Oncol 2001;19:509-18
   Google Scholar
• Stupp R, Mason WP, van den Bent MJ, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352;10:987-96
   Google Scholar
• Reiger J, Roth W, Glaser T, Glioblastoma multiforme: mechanisms of resistence to chemotherapy. Neurol Psychiatr Brain Res 1999;7:37-46
   Google Scholar
• Westphal M, Hilt DC, Bortey E, A Phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 2003;5:79-88
   PubMed Web of Science ®Google Scholar
• Brem H, Piantadosi S, Burger PC, Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet 1995;345:1008-12
   PubMed Web of Science ®Google Scholar
• Patchell RA, Regine WF, Ashton P, A Phase I trial of continuously infused intratumoral bleomycin for the treatment of recurrent glioblastoma multiforme. J Neurooncol 2002;60:37-42
   PubMed Web of Science ®Google Scholar
• Voulgaris S, Partheni M, Karamouzis M, Intratumoural doxorubicin in patients with malignant brain gliomas. Am J Clin Oncol 2002;25:60-4
   PubMed Web of Science ®Google Scholar
• Bobo RH, Laske DW, Akbasak A, Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994;91:2076-80
   PubMed Web of Science ®Google Scholar
• Kunwar, Chang S, Westphal M, Phase III randomized trial of CED of IL13-PE38QR vs Gliadel wafes for recurrent glioblastoma. Neuro-oncol 2010;12:871-81
   PubMedGoogle Scholar
• Brem H, Langer R. Polymer-based drug delivery to the brain. Sci Med 1996;3:52-61
   Google Scholar
• Polifeprosan 20 with carmustine implant [Package insert]. Bloomington, MN: MGI Pharma, Inc., 2006
   Google Scholar
• Olivi A, Ewend MG, Utsuki T, Interstial delivery of carboplatin via biodegradeable polymers is effective against experimental glioma in the rat. Cancer Chemother Pharmacol 1996;39:90-6
   PubMed Web of Science ®Google Scholar
• Shikani AK, Eisele DW, Domb AJ, Polymer delivery of chemotherapy for squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1994;120:1242-7
   PubMed Web of Science ®Google Scholar
• Carmustine package insert. Bedford, OH: Ben Venue Laboratories, Inc., 1998
   Google Scholar
• Fung LK, Ewend M, Sils A, Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide and paclitaxel from a biodegradeable polymer implant in the monkey brain. Cancer Res 1998;58:672-84
   PubMed Web of Science ®Google Scholar
• Brem H, Mahaley MS, Vick NA, Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 1991;74:441-6
   PubMed Web of Science ®Google Scholar
• Tenney JH, Vlahov D, Salcman M, Wide variation in risk of wound infection following clean neurosurgery. J Neurosurg 1985;62:243-7
   PubMed Web of Science ®Google Scholar
• Westphal M, Ram Z, Riddle V, GLIADEL® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter trial. Acta Neurochir 2006;148:269-75
   PubMed Web of Science ®Google Scholar
• Attenello FJ, Mukherjee D, Datoo G, Use of gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 2008;15:2887-93
   PubMed Web of Science ®Google Scholar
• La Rocca RV, Glisson SD, Hargis J, High-grade glioma treated with surgery, carmustine wafer, potoperative radiation and procarbazine, lomustine and vincristine chemotherapy. Neurosurg Q 2005;15:167-71
   Google Scholar
• Pan E, Mitchell SB, Tsai JS, A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J Neurooncol 2008;88:353-7
   PubMed Web of Science ®Google Scholar
• Menei P, Metellus P, Parot-Schinkel, Biodegradable carmustine wafers (gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann Surg Oncol 2010;17:1740-6
   PubMed Web of Science ®Google Scholar
• McGirt MJ, Than KD, Weingart JD, Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 2009;110:583-8
   PubMed Web of Science ®Google Scholar
• La Rocca RV, Vitaz TW, Villaneuva W, A Phase II study of multimodal therapy with surgery, carmustine (BCNU) wafer, radiation (RT) and temozolomide (TMZ) in patients with newly diagnosed supratentorial malignant gliomas. Poster presented at the 8th Congress of the European Association of Neur-Oncology; 12 – 14 September 2008; Barcelona, Spain
   Google Scholar
• Jalali R, Singh P, Menon H, Gujral S. Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with temozolomide. J Neurooncol 2007;85:105-7
   PubMed Web of Science ®Google Scholar
• Bock HC, Puchner JA, Lohmann F, First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev 2010;33:441-9
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi SE, Mason WP, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66
   PubMed Web of Science ®Google Scholar
• Grothey A, Sargent D, Goldberg RM, Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-14
   PubMed Web of Science ®Google Scholar
• Sipos EP, Tyler B, Piantadosi S, Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother Pharmacol 1997;39:383-9
   PubMed Web of Science ®Google Scholar
• Olivi A, Grossman SA, Tatter S, Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol 2003;21:1845-9
   PubMed Web of Science ®Google Scholar
• Murat A, Migliavaca E, Gorlia T, Stem cell-related ‘self-renewal’ signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008;26:3015-24
   PubMedGoogle Scholar
• Stupp R, Hegi ME, Gilbert MR, Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 2007;25:4127-36
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40
   PubMed Web of Science ®Google Scholar
• Sampson JH, Heimberger AB, Archer GE, Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010;28:4722-9
   PubMed Web of Science ®Google Scholar
• Phuphanich S, Rudnick J, Mazer M, Immune response correlation with progression-free survival in glioblastoma following dendritic cell immunotherapy (ICT-107) [abstract 2097]. J Clin Oncol 2010;28:15S
   Google Scholar